- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01181895
Study B2C112060: A Study of the Efficacy and Safety of Vilanterol Inhalation Powder in Adults and Adolescents With Persistent Asthma
9 octobre 2017 mis à jour par: GlaxoSmithKline
A Randomized, Double-blind, Double-dummy, Parallel-group, Placebo Controlled (on Inhaled Corticosteroid Medication), Multicenter Study to Evaluate the Efficacy and Safety of Vilanterol Inhalation Powder (GW642444) and Salmeterol, Compared With Placebo in the Treatment of Persistent Asthma in Adults and Adolescents Uncontrolled on Inhaled Corticosteroids
The objective of this study is to evaluate the efficacy and safety of vilanterol inhalation powder administered once daily in the evening in adolescent and adult subjects 12 years of age and older with persistent asthma over a 12-week treatment period.
Aperçu de l'étude
Statut
Complété
Les conditions
Type d'étude
Interventionnel
Inscription (Réel)
348
Phase
- Phase 3
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
Bayern
-
Gauting, Bayern, Allemagne, 82131
- GSK Investigational Site
-
-
Hessen
-
Frankfurt, Hessen, Allemagne, 60596
- GSK Investigational Site
-
-
Rheinland-Pfalz
-
Mainz, Rheinland-Pfalz, Allemagne, 55131
- GSK Investigational Site
-
-
Schleswig-Holstein
-
Grosshansdorf, Schleswig-Holstein, Allemagne, 22927
- GSK Investigational Site
-
-
-
-
-
Chrzanow, Pologne, 32-500
- GSK Investigational Site
-
Krakow, Pologne, 31-024
- GSK Investigational Site
-
Krakow, Pologne, 31-455
- GSK Investigational Site
-
Krakow, Pologne, 30-901
- GSK Investigational Site
-
Lublin, Pologne, 20-552
- GSK Investigational Site
-
-
-
-
-
Lima, Pérou, Lima 27
- GSK Investigational Site
-
-
Lima
-
Callao, Lima, Pérou, Callao 2
- GSK Investigational Site
-
Lima 27, Lima, Pérou, Lima 27
- GSK Investigational Site
-
San Isidro, Lima, Pérou, Lima 27
- GSK Investigational Site
-
San Miguel, Lima, Pérou, Lima 32
- GSK Investigational Site
-
-
-
-
-
Dnipropetrovsk, Ukraine, 49074
- GSK Investigational Site
-
Dnipropetrovsk, Ukraine, 49027
- GSK Investigational Site
-
Donetsk, Ukraine, 83099
- GSK Investigational Site
-
Ivano-Frankivsk, Ukraine, 76018
- GSK Investigational Site
-
Kharkiv, Ukraine, 61124
- GSK Investigational Site
-
Kharkiv, Ukraine, 61037
- GSK Investigational Site
-
Kyiv, Ukraine, 03680
- GSK Investigational Site
-
Simferopol, Ukraine, 95043
- GSK Investigational Site
-
Yalta, Ukraine, 98603
- GSK Investigational Site
-
-
-
-
California
-
Huntington Beach, California, États-Unis, 92647
- GSK Investigational Site
-
-
Florida
-
Orlando, Florida, États-Unis, 32822
- GSK Investigational Site
-
Tallahassee, Florida, États-Unis, 32308
- GSK Investigational Site
-
-
Georgia
-
Lawrenceville, Georgia, États-Unis, 30046
- GSK Investigational Site
-
-
New Jersey
-
Skillman, New Jersey, États-Unis, 08558
- GSK Investigational Site
-
-
North Carolina
-
Raleigh, North Carolina, États-Unis, 27607
- GSK Investigational Site
-
-
Ohio
-
Cincinnati, Ohio, États-Unis, 45231
- GSK Investigational Site
-
-
Oklahoma
-
Oklahoma City, Oklahoma, États-Unis, 73103
- GSK Investigational Site
-
-
South Carolina
-
Chester, South Carolina, États-Unis, 29706
- GSK Investigational Site
-
Clinton, South Carolina, États-Unis, 29325
- GSK Investigational Site
-
Orangeburg, South Carolina, États-Unis, 29118
- GSK Investigational Site
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
12 ans et plus (Enfant, Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Outpatient at least 12 years of age
- Both genders; females of childbearing potential must be willing to use birth control method
- Clinical diagnosis of asthma for ≥12 weeks
- Best pre-bronchodilator FEV1 of 40%-90% predicted
- Reversibility of FEV1 of at least 12% and 200mls
- Current asthma therapy that include an inhaled corticosteroid for at least 12 weeks prior to 1st visit
- Ability to use replace current short-acting rescue treatment with albuterol and ability to withhold albuterol use for at least 6 hours prior to study visits
Exclusion Criteria:
- History of life-threatening asthma
- Respiratory infection within last 4 weeks leading to change in asthma management
- Asthma exacerbation within last 3 months
- Concurrent respiratory disease or other disease that would confound study participation or affect subject safety
- Allergies to study drugs, study drugs' excipients, or medications related to study drugs
- Taking another investigational medication or medication prohibited for use during the study.
- Previous participation in a vilanterol (GW642444) study
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Vilanterol
Vilanterol inhalation powder once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
|
Vilanterol inhalation powder inhaled orally once daily for 12 weeks
Placebo inhalation powder inhaled orally twice daily for 12 weeks
|
|
Comparateur actif: Salmeterol
Placebo inhalation powder via NDPI once daily + Salmeterol inhalation powder twice daily for 12 weeks
|
Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
|
|
Comparateur placebo: Placebo
Placebo inhalation powder via NDPI once daily + Placebo inhalation powder via Diskus twice daily for 12 weeks
|
Placebo inhalation powder inhaled orally twice daily for 12 weeks
Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change From Baseline in Weighted-mean 24-hour Serial Forced Expiratory Volume in One Second (FEV1) at Week 12
Délai: Baseline and Week 12
|
FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second.
The weighted mean is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, and 30 minutes (min) and at 1, 2, 3, 4, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, respectively, at Week 12.
The Baseline value was the Day 1 pre-dose FEV1 measurement.
Change from Baseline is calculated as the weighted mean 0-24 hour FEV1 (Liters) at Week 12 minus the Baseline value.
Analysis was performed using analysis of covariance (ANCOVA) with covariates of Baseline FEV1, region, sex, age, and treatment.
|
Baseline and Week 12
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change From Baseline in the Percentage of Rescue-free 24-hour (hr) Periods During the 12-week Treatment Period
Délai: Baseline and Weeks 1-12
|
The time span during which the participants did not have to take any rescue bronchodilator (medication intended to relieve symptoms immediately) was considered to be a rescue-free period.
The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization).
Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline.
Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
|
Baseline and Weeks 1-12
|
|
Change From Baseline in the Percentage of Symptom-free 24-hour (hr) Periods During the 12-week Treatment Period
Délai: Baseline and Weeks 1-12
|
Participants who were symptom free for 24-hour periods during the12-week treatment period were assessed.
The Baseline value was derived from the last 7 days of the daily diary prior to the randomization of the participant (including the day of randomization).
Change from Baseline is calculated as the value at Weeks 1-12 minus the value at Baseline.
Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
|
Baseline and Weeks 1-12
|
|
Change From Baseline in Individual Serial FEV1 Assessments at the End of the 12-week Treatment Period, Including the 12-hour and 24-hour Time Points
Délai: Baseline and Week 12
|
FEV1 is a measure of lung function and is defined as the volume of air that can be forcefully exhaled in one second.
The individual serial FEV1 is calculated from the pre-dose FEV1 and post-dose FEV1 measurements at 5, 15, 30, and 60 minutes (min) and 2, 3, 5, 11, 12, 12.5, 13, 14, 16, 20, 23, and 24 hours, relatively, on Treatment Day 84 (Week 12).
The Baseline value was the Day 1 pre-dose FEV1 measurement.
Change from Baseline was calculated as the value of the individual serial FEV1 taken at Week 12 minus the Baseline value.
Analysis was performed using ANCOVA with covariates of Baseline FEV1, region, sex, age, and treatment.
Analysis was performed separately for each planned time point.
|
Baseline and Week 12
|
|
Change From Baseline in Daily Trough (Pre-dose and Pre-rescue Bronchodilator) PM (Evening) Peak Expiratory Flow (PEF) Averaged Over the 12-week Treatment Period
Délai: Baseline and Weeks 1-12
|
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated.
Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug.
The Baseline value is the average value of the last 7 days of daily PM PEF prior to randomization.
Change from Baseline in trough PM PEF was calculated as the averaged value of all daily PM PEF for Week 1 to Week 12 minus the value at Baseline.
Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
|
Baseline and Weeks 1-12
|
|
Change From Baseline in Daily AM (Morning) PEF Averaged Over the 12-week Treatment Period
Délai: Baseline and Weeks 1-12
|
PEF is defined as the maximum airflow during a forced expiration beginning with the lungs fully inflated.
Trough PEF is the PEF measured approximately 24 hours after the last administration of study drug.
The Baseline value is the average value of the last 7 days of daily AM PEF prior to randomization.
Change from Baseline in trough AM PEF was calculated as the averaged value of all daily AM PEF for Weeks 1 to Week 12 minus the value at Baseline.
Analysis was performed using ANCOVA with covariates of Baseline, region, sex, age, and treatment.
|
Baseline and Weeks 1-12
|
|
Number of Participants With the Indicated Time to an Increase of >=12% and >=200 Milliliters (mL) Above Baseline in FEV1 on Day 1 and Day 84 (0-2 Hours)
Délai: Day 1 and Week 12
|
The number of participants with a >=12% and >=200 mL increase from Baseline in FEV1 (the maximal amount of air that can be forcefully exhaled in one second) was evaluated on Day 1 and Week 12 for the time to a >=12% increase from Baseline (at the 5 minutes (min), 15 min, 30 min, 1hour (hr), and 2 hr nominal time points.
Participants who did not achieve a >=12% and >=200 mL increase from Baseline in FEV1 over this time period were considered censored.
|
Day 1 and Week 12
|
|
Number of Participants With the Indicated Global Assessment of Change Questionnaire Responses at the End of Week 4 and Week 12
Délai: Week 4 and Week 12
|
At the end of Week 4 and Week 12, the Global Assessment of Change Questionnaire, which assesses changes in asthma symptoms and rescue medication use, was completed by participants using the following scale: asthma symptom (AS) change: much better, somewhat better, a little better, the same, a little worse, somewhat worse, much worse; rescue medication use (RMU): much less often , somewhat less often , a little less often , the same , a little more often , somewhat more often , much more often.
|
Week 4 and Week 12
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 septembre 2010
Achèvement primaire (Réel)
1 août 2011
Achèvement de l'étude (Réel)
26 août 2011
Dates d'inscription aux études
Première soumission
15 juillet 2010
Première soumission répondant aux critères de contrôle qualité
12 août 2010
Première publication (Estimation)
13 août 2010
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
8 novembre 2017
Dernière mise à jour soumise répondant aux critères de contrôle qualité
9 octobre 2017
Dernière vérification
1 octobre 2017
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Maladies des voies respiratoires
- Maladies du système immunitaire
- Maladies pulmonaires
- Hypersensibilité immédiate
- Maladies bronchiques
- Maladies pulmonaires obstructives
- Hypersensibilité respiratoire
- Hypersensibilité
- Asthme
- Effets physiologiques des médicaments
- Agents adrénergiques
- Agents neurotransmetteurs
- Mécanismes moléculaires de l'action pharmacologique
- Agents autonomes
- Agents du système nerveux périphérique
- Agonistes adrénergiques
- Agents bronchodilatateurs
- Agents anti-asthmatiques
- Agents du système respiratoire
- Agonistes des récepteurs bêta-2 adrénergiques
- Bêta-agonistes adrénergiques
- Xinafoate de salmétérol
Autres numéros d'identification d'étude
- 112060
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
OUI
Description du régime IPD
Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.
Données/documents d'étude
-
Rapport d'étude clinique
Identifiant des informations: 112060Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulaire de rapport de cas annoté
Identifiant des informations: 112060Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Formulaire de consentement éclairé
Identifiant des informations: 112060Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Plan d'analyse statistique
Identifiant des informations: 112060Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Ensemble de données de participant individuel
Identifiant des informations: 112060Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Protocole d'étude
Identifiant des informations: 112060Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
-
Spécification du jeu de données
Identifiant des informations: 112060Commentaires d'informations: For additional information about this study please refer to the GSK Clinical Study Register
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .